CD86 and neoplasm: However, doxorubicin treatment upregulated M1 marker MHC-II, inducible nitric oxide synthase (iNOS) and CD86 (Fig. 2a–c), and downregulated M2 marker Arginase 1 and CD206 (Fig. 2d, e) on tumor-associated macrophages.